Your browser doesn't support javascript.
The early start of hemoperfusion decreases the mortality rate among severe COVID-19 patients: A preliminary study.
Mikaeili, Haleh; Taghizadieh, Ali; Nazemiyeh, Masoud; Rezaeifar, Parisa; Zununi Vahed, Sepideh; Safiri, Saeid; Ardalan, Mohammadreza; Ansarin, Khalil.
  • Mikaeili H; Tuberculosis and Lung Disease Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Taghizadieh A; Tuberculosis and Lung Disease Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Nazemiyeh M; Tuberculosis and Lung Disease Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rezaeifar P; Tuberculosis and Lung Disease Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Zununi Vahed S; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Safiri S; Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ardalan M; Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ansarin K; Rahat Breath and Sleep Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hemodial Int ; 26(2): 176-182, 2022 04.
Article in English | MEDLINE | ID: covidwho-1570641
ABSTRACT

BACKGROUND:

Coronavirus disease-2019 (COVID-19)-related organ failure is partly related to a sepsis-like syndrome and extreme pro-inflammatory cytokine release, named cytokine storm. Therapeutic strategies that prevent the production of or remove the pro-inflammatory cytokines could potentially be an effective therapy in critically afflicted COVID-19 patients.

METHODS:

In this clinical trial study, from April until June 2020, 68 COVID-19 patients (35 vs. 33 controls) with severe critical symptoms, and PaO2 /FiO2 (P/F) ratio less than 200 mmHg either received a single standard therapy or a combination of standard treatment for COVID-19 combined with hemoperfusion (hemofilter, HA330 D Javfron) for 4 h, in 3 consecutive days. The length of hospital stay and mechanical ventilation, the resolution of radiologic abnormalities, and the mortality rate were defined as the primary outcomes.

RESULTS:

Demographic characteristics, the acute physiology, and chronic health evaluation score of both groups were similar (p > 0.05). Importantly, we noticed a significant mortality rate reduction in the perfused group compared with controls (37.1% vs. 63.6%, p = 0.02), this positive effect was stronger among those with a P/F ratio higher than 75 (mortality rate of 84.7% for P/F ratio < 75 vs. 15.4% for P/F ratio ≥ 75, p = 0.02).

CONCLUSIONS:

The results imply that early start of hemoperfusion could be more effective and significantly reduce the mortality rate among COVID-19 patients with critical diseases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hemoperfusion / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Hemodial Int Journal subject: Nephrology / Therapeutics Year: 2022 Document Type: Article Affiliation country: Hdi.12982

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hemoperfusion / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Hemodial Int Journal subject: Nephrology / Therapeutics Year: 2022 Document Type: Article Affiliation country: Hdi.12982